The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Congresses
Poster
I-DXd, R-DXd
ESMO 2025 | October 17-21, 2025
Lung Cancer
KEYMAKER-U01 phase 2 substudies 01H/01I: Ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd), or docetaxel in stage IV non–small-cell lung cancer
Ernest Nadal
View presentation
Poster
T-DXd, Other/Multi
ESMO 2025 | October 17-21, 2025
Breast Cancer
Long-term survival outcomes in patients with HER2+ metastatic breast cancer treated with trastuzumab and pertuzumab: A 2012–2024 US real-world analysis
Arielle Heeke
View presentation
Poster
Dato-DXd, Valemetostat
ESMO 2025 | October 17-21, 2025
Lung Cancer
Phase 1b study of valemetostat in combination with datopotamab deruxtecan (Dato-DXd) in advanced non-squamous non-small-cell lung cancer (NSCLC): Initial safety results
Alexander Spira
View presentation
Oral
R-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: Primary analysis of the phase 2, dose-optimization part of the REJOICE-Ovarian01 study
Isabelle Ray-Coquard
View presentation
Poster
R-DXd
ESMO 2025 | October 17-21, 2025
Gastric Cancer
Raludotatug deruxtecan in participants with gastrointestinal cancers: Phase 2 REJOICE-GI01 trial
Makoto Ueno
View presentation
Poster
Other/Multi
ESMO 2025 | October 17-21, 2025
Lung Cancer
Real-world survival outcomes for docetaxel-containing regimens for patients with locally advanced or metastatic non-small cell lung cancer in England who have progressed on current standard of care
Andrew Thompson
View presentation
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gastric Cancer
Risk of HBV reactivation in patients with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan in DESTINY-Gastric06
Lin Shen
View presentation
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Breast Cancer
The effectiveness of post–trastuzumab deruxtecan (T-DXd) treatment regimens and the incidence of recurrent interstitial lung disease (ILD) in patients with HER2+ metastatic breast cancer who discontinued T-DXd due to ILD
Junji Tsurutani
View presentation
Oral
T-DXd
ESMO 2025 | October 17-21, 2025
Breast Cancer
Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer: Additional analyses of DESTINY-Breast09 in key subgroups of interest
Sibylle Loibl
View presentation
Mini-Oral
T-DXd
ESMO 2025 | October 17-21, 2025
Colorectal Cancer
Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase 2 trial
Kanwal Raghav
View presentation
Pages: 1  2  3  
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24